Phi Pharma SA

Swiss Biotech Association

Not a member

Phi Pharma SA is developing a new class of anti-cancer drugs: peptide drug conjugates effective in multiple human cancers using an innovative mechanism of cell entry: novel sugar-based drug targets.

https://www.phi-pharma.com/

Location

Place du Midi 36, 1950 Sion, Switzerland

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2012
Number of employees in Switzerland

1-9

Key business

Core competencies

You may also be interested in

Cell Receptor SA

Cell Receptor Inc. has IP for improving results in oncological treatment by targeting upstream steps of growth signaling, not noticed in oncology yet. A well-tolerated affordable treatment of low toxicity! It will prevent metastasis in most cancers.
www.nature.com/articles/d43747-021-00133-8
1208 Geneva

Member

D36.ch Sarl

D36.ch is an innovative startup with a strong engineering DNA that empowers companies in healthcare and life sciences sectors throughout their digital transformation journeys. We offer a combination of products and services building a thriving digital healthcare technology landscape.
1588 Cudrefin

Member

SICPA SA

Founded in 1927, SICPA is an international company whose purpose is to Enable Trust, providing governments and authorities with unique solutions for secured authentication, identification and traceability, developping solutions that will further help authorities monitor and anticipate health risks.
1008 Prilly

Member